Archive for the ‘Biosolutions’ Category
CEO took roundabout path to Emergent
By Marjorie Censer
Monday, January 3, 2011
Fuad El-Hibri has lived in all sorts of exotic locales, working for Citicorp in Saudi Arabia, consulting for Booz Allen Hamilton in Indonesia and establishing mobile telecommunications businesses in Russia, Venezuela and El Salvador.
But getting started in his current position as chief executive of Rockville-based pharmaceutical company Emergent BioSolutions took [...]
January 7, 2011
Tags: Chief executive officer, Department of Health and Human Services, El-Hibri, Emergent BioSolutions Inc., entrepreneur, Rockville Posted in: Biosolutions, Business, CEO, Department of Health and Human Services, El-Hibri, Emergent BioSolutions, Research and development, Trubion Pharmaceuticals, Yale University, fuad, fuad el-hibri 
No Comments
Fuad El-Hibri and the International Biomedical Research Alliance
The International Biomedical Research Alliance (IBRA) is a philanthropic organization that is dedicated to the support of the NIH-Oxford-Cambridge Scholars Program, which strives to establish the highest standards of excellence in training biomedical researchers, advance groundbreaking biomedical research, enrich the pool of leaders in the field, and eliminate barriers which frustrate [...]
November 13, 2010
Tags: Anthrax vaccines, Emergent BioSolutions, Food and Drug Administration, fuad el-hibri, Infectious disease, Leadership, Medical research Posted in: Biosolutions, Biothrax, El-Hibri, Emergent BioSolutions, Research and development, fuad el-hibri No Comments
Emergent BioSolutions to Release Third Quarter 2010 Financial Results and Conduct a Conference Call on November 4, 2010
ROCKVILLE, Md., Oct 13, 2010 — Emergent BioSolutions Inc. (NYSE: EBS) announced today it will report financial results for third quarter 2010 on Thursday November 4, 2010, after market close. Company management will host a conference call at 5:00 pm Eastern on November 4, 2010 to discuss the financial results for [...]
October 23, 2010
Tags: Anthrax, Anthrax vaccines, Chief executive officer, Conference call, Emergent BioSolutions, Food and Drug Administration, fuad el-hibri, New York Stock Exchange Posted in: Anthrax vaccines, Biosolutions, Biothrax, Emergent BioSolutions, fuad el-hibri No Comments
Emergent BioSolutions Awarded HHS Contract Valued at up to $186.6 Million to Develop rPA Anthrax Vaccine
ROCKVILLE, MD, September 17, 2010 – Emergent BioSolutions Inc. (NYSE:EBS) announced today that it has signed a contract, valued at up to $186.6 million, with the Biomedical Advanced Research and Development Authority (BARDA) of the Department of Health and Human Services (HHS), for the development of a recombinant protective antigen [...]
September 20, 2010
Tags: Anthrax vaccines, Clinical trial, Emergent BioSolutions, Food and Drug Administration, Research and development, U.S. Government Posted in: Anthrax vaccines, Biosolutions, Emergent BioSolutions, Research and development, fuad el-hibri No Comments
Emergent BioSolutions Hosts Symposium for Biomedical Research Scholars
ROCKVILLE, Md., Aug 24, 2010 (BUSINESS WIRE) — Emergent BioSolutions Inc. (NYSE:EBS) today hosted “Looking Beyond the Bench,” a symposium organized for doctoral students enrolled in the NIH-Oxford-Cambridge Scholars Program. The symposium featured Emergent executives, who, based on their extensive experience in the biopharmaceutical industry, [...]
August 30, 2010
Tags: Anthrax vaccines, BioSolutions Inc, Chief executive officer, Emergent BioSolutions, Food and Drug Administration, fuad el-hibri, Infectious disease, Scholars Program Posted in: Anthrax vaccines, Biosolutions, Business, El-Hibri Peace Education Prize, Emergent BioSolutions, Infectious disease, Scholars Program, fuad el-hibri No Comments
Emergent BioSolutions to Acquire Trubion Pharmaceuticals
Trubion provides promising clinical-stage therapeutic candidates in the targeted disease areas of oncology and autoimmunity
Trubion offers novel, protein therapeutic platforms and scientific expertise for developing innovative therapeutic candidates
Transaction leverages large pharma partnerships to provide sales and marketing infrastructureidates
Emergent reaffirms 2010 guidance for revenues and net income
ROCKVILLE, Md., Aug 12, 2010 (BUSINESS WIRE) –
Emergent BioSolutions Inc. [...]
August 19, 2010
Tags: Biosolutions, Board of Directors, Common stock, Emergent BioSolutions, Seattle, Stock, Systemic Lupus Erythematosus, Trubion Pharmaceuticals Posted in: Africa, Anthrax vaccines, Biosolutions, Emergent BioSolutions, Health Care, Management, Research and development, Share, Trubion Pharmaceuticals, fuad el-hibri No Comments
Emergent BioSolutions Awarded HHS Contract Valued at Up to $107 Million to Develop Large-Scale Manufacturing for BioThrax
ROCKVILLE, Md., Jul 14, 2010
Emergent BioSolutions Inc. (NYSE:EBS) announced today that it has signed a contract valued at up to $107 million with the Office of the Biomedical Advanced Research and Development Authority (BARDA) of the Department of Health and Human Services (HHS), to develop and obtain regulatory approval for large-scale [...]
July 15, 2010
Tags: Anthrax vaccines, Biothrax, Emergent BioSolutions, Food and Drug Administration, Infectious disease, US government Posted in: Anthrax vaccines, Biosolutions, Biothrax, Emergent BioSolutions, Health Care, fuad el-hibri No Comments
Emergent BioSolutions Chairman and CEO Fuad El-Hibri Recognized as Outstanding International Business Leader
ROCKVILLE, Md., Mar 11, 2010 (BUSINESS WIRE) — Emergent BioSolutions Inc. (EBS 15.96, -0.03, -0.19%) announced today that Fuad El-Hibri, its chairman and chief executive officer, has been named by the World Trade Center Institute (WTCI) as one of Maryland’s outstanding international business leaders. Celebrating the spirit of global ambition and excellence in international leadership, [...]
March 15, 2010
Tags: Business, Chief executive officer, Emergent BioSolutions, fuad el-hibri, Leadership, Maryland Posted in: Biosolutions, Business, Emergent BioSolutions, Management No Comments
500 Most Influential Muslims: Science and Technology
The Prince Alwaleed Bin Talaal Center for Muslim-Christian Understanding and The Royal Islamic Strategic Studies Centre published its first edition in what promises to be an annual series of insight into the movers and shakers of the Muslim world. Entitled The 500 Most Influential Muslims 2009, the book categorizes Muslims’ influential capacities into 15 [...]
January 6, 2010
Tags: Emergent BioSolutions, fuad el-hibri, Middle East, Muslim world, Washington DC Posted in: Biosolutions, CEO, Emergent BioSolutions, Washington, fuad el-hibri No Comments
Fuad el-Hibri, king of anthrax, wins an award from Ernst & Young
Marie-JosГ© Daoud
Awarded the Ernst and Young prize for Entrepreneur of the year 2009 in the Technology category for the Greater Washington region last June, Fuad El-Hibri is the CEO of Emergent Biosolutions, an American company that supplies the anthrax vaccine to the American government. He is in line for the national E&Y 2009 prize, which [...]
December 17, 2009
Tags: Emergent BioSolutions, Ernst & Young, Federal government of the United States, Food and Drug Administration, Porton Product, United States. Posted in: Biosolutions, Department of Health and Human Services, El-Hibri, Emergent BioSolutions, fuad el-hibri No Comments